Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05052567

CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1b/2 Clinical Study on Safety, Pharmacokinetics, and Preliminary Efficacy of CEND-1 for Injection in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

Sponsor: Cend Therapeutics Inc.

Conditions Pancreatic Cancer

Interventions CEND-1

Updated 6 times since 2021 Last updated: Aug 30, 2024 Started: Oct 21, 2021 Primary completion: Jun 29, 2024 Completion: Jun 29, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Pancreatic Cancer and is currently completed. Cend Therapeutics Inc. leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Oct 2024 — Present [monthly]

Completed PHASE1/PHASE2

Status: Unknown → Completed
Sep 2024 — Oct 2024 [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Feb 2024 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Feb 2023 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Oct 2021 — Feb 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cend Therapeutics Inc.
Qilu Pharmaceutical Co., Ltd.

Data source: Qilu Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China